ClinicalTrials.gg
CompletedNCT02137070WISEBrainUpdated Dec 5, 2024Results posted

The WISE (Weightloss Intervention Surgical Effects) Brain Study

An observational study in Diabetes and Weightloss, sponsored by University of Florida. Completed at 1 site in United States. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by University of Florida · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
197
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This study is being done to learn about the changes that weight loss causes on brain function, memory and thinking ability in adults. The study does NOT cover any costs associated with bariatric surgery.

Read the detailed description

There will be two groups of people studied:

One group has chosen (independently of this research study) to have weight loss surgery to help them lose weight.

Another group will not choose to have any weight loss surgery. All research participants will be tested on thinking and memory processes at the start of the study, after 12 weeks, and again at 18 months. They will have an MRI Brain Scan at those same times also to look at changes in the structure and function of the brain tissue.

Blood tests will be done to measure the sugar levels in the blood, and other proteins that may act as markers for disease.

02

Conditions studied

  • Diabetes
  • Weightloss

Keywords

  • Weightloss and brain function
  • Effects of bariatric surgery on brain function
  • Reduced glucose insulin changes and brain function
03

In context

Diabetes Mellitus

11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 197 is below the median of 234 across 2,254 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of Florida is the lead sponsor of 1,285 studies on the registry; 199 are open to participants now.

Of its 177 completed or terminated interventional studies of FDA-regulated products, 141 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Potential bariatric surgery patients will have study specific information made available to them for their consideration at the bariatric or diabetes clinics at UFHealth \& Shands Hospital, or at other community locations. Flyers will be posted in many community advertising locations in the North Florida region. Prospective participants must live in Gainesville, FL or the surrounding areas to be eligible.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body Mass Index >35
  • Diabetes or no diabetes
  • Compatible with MRI Scanning
  • Willing to give a small blood sample on 3 occasions
  • Capable of providing informed consent

Exclusion criteria

Exclusion Criteria:

  • Prior neurological disorder
  • Mini Mental Status Exam score
  • Major psychiatric disturbance (schizophrenia, chronic intractable depression,
  • Coronary revascularization, peripheral vascular disease
  • Severe cardio vascular disease history
  • Unstable medical conditions (cancer)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
197 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Bariatric Surgery Candidates

    Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH \& Shands Hospital.

    Procedure: Bariatric Surgery Candidates

  • Non surgical/Community volunteers

    Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss

    Other: Non surgical/Community volunteers

Interventions

  • ProcedureBariatric Surgery Candidates

    Participants who are intending to have bariatric surgery for weight loss

  • OtherNon surgical/Community volunteers

    Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss

06

What researchers measure

Primary outcomes

  1. Change in BOLD fMRI Signal

    Brain activation changes will change in the frontal cortex and hippocampus. * z-score is a transformation of the Pearson's (r) correlation coefficient of the BOLD timeseries between two brain regions * a value of \< 0 suggests a weakening of the connections between brain areas; and a value of \> 0 suggests a strengthening of the connections between brain areas * A value of r=0 indicates that two brain regions were functionally disconnected

    Time frame: Change from baseline at 18 months

07

Results

Posted Dec 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneBariatric Surgery CandidatesNon Surgical/Community Volunteers
Started15047
Completed7629
Not completed7418
Withdrew: Adverse event123
Withdrew: Death20
Withdrew: Lost to follow-up249
Withdrew: Physician decision01
Withdrew: Protocol violation184
Withdrew: Withdrawal by subject181

Outcome measures

PrimaryChange in BOLD fMRI Signal

Brain activation changes will change in the frontal cortex and hippocampus. * z-score is a transformation of the Pearson's (r) correlation coefficient of the BOLD timeseries between two brain regions * a value of \< 0 suggests a weakening of the connections between brain areas; and a value of \> 0 suggests a strengthening of the connections between brain areas * A value of r=0 indicates that two brain regions were functionally disconnected

Time frame:
Change from baseline at 18 months
Reported as:
Mean · Connectivity Fisher-z transformation
Change in BOLD fMRI Signal
Connectivity Fisher-z transformationBariatric Surgery CandidatesNon Surgical/Community Volunteers
Baseline - Seed (R Hippocampus) to cluster (MNI -44 -26 46)0.10 ± 0.100.08 ± 0.09
Follow-up - Seed (R Hippocampus) to cluster (MNI -44 -26 46)0.18 ± 0.13-0.01 ± 0.13
Baseline - Seed (L Hippocampus) to cluster (MNI 16, -24, 56)0.09 ± 0.090.09 ± 0.10
Follow-up - Seed (L Hippocampus) to cluster (MNI 16, -24, 56)0.16 ± 0.14-0.03 ± 0.14
Baseline - Seed (R Frontal Pole) to cluster (MNI 60, -26, 24)0.07 ± 0.090.10 ± 0.09
Follow-up - Seed (R Frontal Pole) to cluster (MNI 60, -26, 24)0.21 ± 0.160.03 ± 0.14
Baseline - Seed (L Frontal Pole) to cluster (MNI 60, 08, -30)0.05 ± 0.100.10 ± 0.07
Follow-up - Seed (L Frontal Pole) to cluster (MNI 60, 08, -30)0.16 ± 0.110.00 ± 0.10
Baseline - Seed (R Inferior Frontal Gyrus) to cluster (MNI -66, -24, -20)0.12 ± 0.090.15 ± 0.08
Follow-up - Seed (R Inferior Frontal Gyrus) to cluster (MNI -66, -24, -20)0.24 ± 0.090.09 ± 0.10
Baseline - Seed (R Inferior Frontal Gyrus) to cluster (MNI 40, -22, 52)0.22 ± 0.120.20 ± 0.10
Follow-up - Seed (R Inferior Frontal Gyrus) to cluster (MNI 40, -22, 52)0.34 ± 0.100.14 ± 0.12
Baseline - Seed (R Inferior Frontal Gyrus) to cluster (MNI 02, -38, 66)0.14 ± 0.120.12 ± 0.11
Follow-up - Seed (R Inferior Frontal Gyrus) to cluster (MNI 02, -38, 66)0.25 ± 0.130.06 ± 0.12
Baseline - Seed (L Inferior Frontal Gyrus) to cluster (MNI 32, 14, -16)0.12 ± 0.110.11 ± 0.09
Follow-up - Seed (L Inferior Frontal Gyrus) to cluster (MNI 32, 14, -16)0.22 ± 0.090.01 ± 0.10
Baseline - Seed (Anterior Cingulate) to cluster (MNI 60, -06, -04)0.07 ± 0.100.10 ± 0.10
Follow-up - Seed (Anterior Cingulate) to cluster (MNI 60, -06, -04)0.17 ± 0.100.00 ± 0.13
Statistical analysis
  • Bariatric Surgery Candidates vs Non Surgical/Community Volunteers · 2x2 Factorial ANOVA in CONN · p = <0.01 (Voxel-size (p-FWE \< 0.01) and voxel-peak (p-unc \< 0.001) were corrected for multiple comparisons.)2x2 Factorial ANOVA in CONN - Group (Bariatric surgery vs. control) \& time (pre-surgery baseline vs. 18-month follow-up)

Adverse events

Collected over 18 months. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Surgical Group2/150 (1.3%)5/150 (3.3%)11/150 (7.3%)
Control Group0/47 (0%)0/47 (0%)3/47 (6.4%)
Most frequent serious events
Most frequent serious events
EventSurgical GroupControl Group
Post-surgical SymptomsGastrointestinal disorders3/1500/47
High BDIPsychiatric disorders2/1500/47
Most frequent other events
Most frequent other events
EventSurgical GroupControl Group
MRI symptomsGeneral disorders4/1502/47
Blood draw problemsGeneral disorders3/1501/47
Survey Questions/Cognitive questionsSocial circumstances3/1500/47
Other tasksGeneral disorders1/1500/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
<=18 years000
Between 18 and 65 years14342185
>=65 years7512
Age, Continuous
Age, Continuous(years)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
Mean42.54 ± 11.5152.29 ± 12.5144.86 ± 12.44
Age, Customized
Age, Customized(years)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
Mean by intervention condition42.54 ± 11.5152.29 ± 12.5144.86 ± 12.44
Sex: Female, Male
Sex: Female, Male(Participants)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
Female11832150
Male321547
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
Hispanic or Latino11415
Not Hispanic or Latino13843181
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American351449
White10031131
More than one race000
Unknown or Not Reported15217
Region of Enrollment
Region of Enrollment(participants)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
United States15047197
Age of study participants
Age of study participants(years)Bariatric Surgery CandidatesNon Surgical/Community VolunteersTotal
Mean42.54 ± 11.5152.29 ± 12.5144.86 ± 12.44
08

Study locations

1 site
  • University of Florida - College of Public Health and Health Professions
    Gainesville, Florida 32611, United States
09

References and documents

Publications

  • Fernando HJ, Cohen RA, Gullett JM, Friedman J, Ayzengart A, Porges E, Woods AJ, Gunstad J, Ochoa CM, Cusi K, Gonzalez-Louis R, Donahoo WT. Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities. Obesity (Silver Spring). 2019 Jul;27(7):1099-1106. doi: 10.1002/oby.22508. Epub 2019 May 22. PubMed 31116012 ↗

Study documents

  • Study protocol · Jan 20, 2022
  • Protocol and informed consent form · Jan 3, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Nov 2022, 99 months.

Results were first posted in Dec 2024, 2 years 1 month after primary completion.

Of 630 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 130. This study's 99 months is above that.

Counting every sponsor, half of 771 studies reached it within 36 months; a quarter within 15 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2014
First posted
May 13, 2014
StartActual
Aug 2014
Primary completionActual
Nov 2022
CompletionActual
Nov 2022
Results first posted
Dec 5, 2024
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02137070
Responsible party
Sponsor
First posted
May 13, 2014
Start date
Aug 2014
Primary completion
Nov 2022
Completion
Nov 2022
Results posted
Dec 5, 2024
Last update
Dec 5, 2024

Study contacts

Ronald A Cohen, PHD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion